Redeye provides a research update following the Q2 report recently published by Isofol. Overall, there were no large surprises, with only a slightly higher OPEX than anticipated. Despite some difficulties in the patient recruitment in the ongoing Phase Ib/Phase II study, we continue to have a positive outlook on the case. The 120, 200 and 300 mg/m² dose cohorts have been completed without dose-limiting toxicities, and the final 500 mg/m² cohort has now been initiated. Following Redeye's new valuation approach, which factors in both fundamental valuation and relative valuation, we assign Isofol a new fair value of SEK1.7 per share.
LÄS MER
